Benefit-Risk Assessment, Communication, and Evaluation (BRACE)

(14) A Comprehensive Review on The Teratogenic Risks for Twelve Drugs with Risk Evaluation and Mitigation Strategy (REMS) to Prevent Prenatal Exposure

(G) Thiazide Diuretics and The Risk of Skin Cancer: A Meta-Analysis of Observational Studies

(Y) An Approach to Personalized Assessment of Drug Efficacy Using Likelihood Ratios

(W) Benefit Risk Contextualisation of COVID-19 Vaccines in the EU

(V) Regulatory Benefit-Risk Assessment of Oncology Drugs: A Systematic Review of FDA and EMA Approvals

(X) Structured Benefit-Risk for Enoxaparin Based on Real World Evidence Data in The Context of Its Label Extension for Treatment of Deep Vein Thrombosis and Pulmonary Embolism and Prevention of Its Recurrence in Active Cancer Patients

(11) A Review of Patient-Reported Outcomes for European Medicines Agency Regulatory Approval of Oncologic Drugs Between 2017 and 2020

(2) Application of The BRACE Framework for Benefit-Risk Assessment, Communication, and Evaluation of Pexidartinib

(15) Contribution of Real-World Evidence to Support Efficacy Claims in Centralised Marketing Authorisation Applications Submitted to EMA in 2018-2019

(13) Effectiveness of Risk Minimization Plan for Concentrated Insulin Lispro in France, Germany and Sweden

(3) Estimates of Dietary Exposure to Antibiotics Among a Community Population in East China

(4) Evaluation of Consumers' Knowledge, Beliefs and Risk Assessment Regarding Protein

(6) Fetal Exposure to Isotretinoin in Saudi Arabia: Real-World Data Analysis from 2015-2020

(5) Guidance for Pediatric Use in Prescription Information for Novel Medicinal Products in The EU and the US

(10) Letermovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation

(1) Pharmacoepidemiology and Benefit/Risk Management Strategies in Clinical Trials with Cell-Based Combination Products

(8) Prenatal Exposure to Teratogenic Drugs: Contrasts Between Publicly and Privately Insured Persons

(9) Readability of Information Imprinted in Patient Information Leaflets (PILs) in Saudi Arabia: The Case of Antihypertensive Medications

(7) Research Impact Assessment: An Example from The Canadian Network for Observational Drug Effect Studies

(12) Targets for Quality Improvement? Top 10 Teratogenic Drugs Used During Pregnancy in the US